ClinicalTrials.gg
CompletedNCT05985694Updated Sep 10, 2025

AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

A Phase 1/2 interventional study of AD17002 and Placebo in Eosinophilic Asthma, sponsored by Advagene Biopharma Co. Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Advagene Biopharma Co. Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are

  1. Could the AD17002 intranasal immunomodulator improve the clinical condition of eosinophilic asthmatic patients?
  2. Could patients self-administer AD17002 via the intranasal route?
  3. Is the AD17002 at multiple doses safe for asthmatic patients?
  4. Participants will be asked to self-administer two doses per week for a total of 6 weeks (11 doses). A diary on AD17002 usage, adverse events, and reliever medication will be recorded.
Read the detailed description

This study was conducted to determine the potential efficacy and mechanism of AD17002 as an immunomodulator in attenuating the severity of clinical manifestations in patients with unstable, moderate-to-severe eosinophilic asthma. Patients with clinical history and ongoing eosinophilic asthma will be randomly assigned to either AD17002 (10 μg or 20 μg) or placebo, per 3-4 days, in a 1:1 ratio, in a single-blinded (patient-blinded) fashion. The nasal administration will be self-administered by participants. Progression and improvement in asthmatic symptoms will be recorded. All study subjects will sign ethics committee-approved informed consent forms before participating in any trial-related activities. Subjects who participate in this trial of AD17002 will provide information about the dosing, efficacy, and safety of the new indication that will guide its future clinical use.

02

Conditions studied

  • Eosinophilic Asthma

Keywords

  • LTh(αK), Type I/III Interferon, Immunomodulator, epithelial
03

In context

Lead sponsor

Advagene Biopharma Co. Ltd. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject 20-80 years of age on the day of signing
  2. Subject who is not a current smoker with poorly controlled, moderate to severe eosinophilic asthma based on GINA 2022 criteria.
  3. The subject is diagnosed with asthma.
  4. Subjects who have the post-bronchodilator reversibility of Forced expiratory volume 1 () of ≥ 12% and ≥ 200 mL in response to a SABA at the screening visit or documented in the medical chart within 3 months of the screening visit.
  5. Subjects who have ≥3% eosinophil counts in the induced sputum within 7 days of Visit 1.
  6. Subjects with ACT scores ≤ 19 under regular low to moderate-dose inhaled (ICS) and/or a combination with inhaled long-acting beta 2 agonists for at least 3 months before the Screening Visit.
  7. Have a negative serum pregnancy test at the screening, and randomization visits (female subjects of ). A female subject who is of agrees to remain abstinent or use (or have their partner use) an acceptable method of within the projected duration of the trial. Acceptable birth control methods are intrauterine devices, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condoms, and vasectomy, as per local regulations or guidelines.
  8. A female subject who is not of reproductive potential is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who has either
  9. Reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the range as determined by the laboratory, or 12 months of spontaneous amenorrhea),
  10. Six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or
  11. Bilateral tubal ligation.
  12. Subject or the subject's legal representative understands the trial procedures, alternative treatments available, and risks involved with the trial, and voluntarily agrees to participate by giving written informed consent.
  13. Provide written informed consent for the trial and be willing to adhere to dose and visit schedules.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with serious underlying chronic illness or severe systemic disease, including SLE, malignant diseases, uremia and heart failure, or abnormal liver function.
  2. Subjects without a recent respiratory tract infection within 3 weeks before the study.
  3. Subjects without a recent COVID-19 infection within 1 month before study.
  4. Subjects with lung disease, including but not limited to (Chronic Obstructive Pulmonary Disease), chronic respiratory infection, lung cancer, etc.
  5. Arrhythmia, myocardial infarction, or stroke in the last 3 months.
  6. Active COVID-19 disease (SARS-CoV-2 Lateral flow tests (LFA)-positive) at Screening.
  7. A clinical history of persistent allergic asthma or rhinitis caused by an allergen to which the subject is regularly exposed and sensitized.
  8. A clinical history of active chronic sinusitis (> 3 months).
  9. Any clinically relevant chronic disease (>=3 months duration) (e.g. cystic fibrosis, , renal or hepatic insufficiency).
  10. Subject with a documented history of Bell's palsy.
  11. The subject has any nasal condition that could confound the efficacy or safety assessments.
  12. treatment (ATC code L04 or L01) within 3 months before the screening visit (except the specified concomitant medications for allergy and asthma symptoms).
  13. Has unstable or severe asthma, as judged by the clinical Investigator, or a subject who has experienced a life-threatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic (but allowing SABA) at any time within the last 3 months before Screening Visit.
  14. Has asthma requiring high-dose oral corticosteroid (OCS) within the last 3 months before Screening Visit.
  15. Has a history of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, unknown cause, or inhalant allergen.
  16. Is pregnant or expecting to conceive within the projected duration of the trial.
  17. Is nursing at randomization and within the projected duration of the trial?
  18. Has had previous exposure to the study drug or Flu Vaccine AD07030.
  19. The subject is receiving ongoing treatment with any specific immunotherapy at the time of the Screening Visit.
  20. Has a known history of allergy, , or intolerance to medicinal products, rescue medications, or self-injectable epinephrine.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    Cohort 1 Placebo

    Formulation buffer

    Drug: Placebo

  • Experimental
    Cohort 1 Low dose

    Formulation buffer + 10 μg AD17002

    Drug: AD17002

  • Placebo comparator
    Cohort 2 Placebo

    Formulation buffer

    Drug: Placebo

  • Experimental
    Cohort 2 High dose

    Formulation buffer + 20 μg AD17002

    Drug: AD17002

Interventions

  • The dosing days of AD17002 are: Days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32.

    Also known as: LTh(αK)

  • DrugPlacebo

    Formulation buffer. Dosing days: 1, 4, 8, 11, 15, 18, 22, 25, 29, 32.

    Also known as: Formulation buffer

06

What researchers measure

Primary outcomes

  1. FEV1 improvement

    Lung function tests with spirometry

    Time frame: Day 1 to Day 78

Secondary outcomes

  1. Change to the use of Short-Acting Beta Agonists (SABA)

    The number of use of rescue Short-Acting Beta Agonists

    Time frame: Day 1 to Day 78

  2. Fractional exhaled nitric oxide (FeNO) change

    Change to the FeNO levels

    Time frame: Day 1 to Day 78

  3. changes of sputum eosinophil counts

    Change to the induced sputum eosinophils' count

    Time frame: Day 1 to Day 78

  4. Asthma Control Test (ACT) scores improvement

    Change to the ACT scores. A maximum score of 25 points indicates complete asthma control. A score between 20 and 25 represents well controlled asthma, while a score of 19 or below represents not well controlled asthma, and a score less than 16 indicates very poorly controlled asthma.

    Time frame: Day 1 to Day 78

  5. Corticosteroid used to control asthma

    Numbers of corticosteroid used, inhaled or oral

    Time frame: Day 1 to Day 78

  6. Immunological biomarkers of sputum

    Changes in the concentration of sputum IL-4, -5, -13, IFN-α, eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) from the baseline

    Time frame: Day 1 to Day 78

  7. Immunological biomarkers of serum

    Change of concentration from baseline of induced serum IL-4, -5, -13

    Time frame: Day 1 to Day 78

  8. Peripheral eosinophil count

    Change of cell numbers from baseline of peripheral eosinophil count

    Time frame: Day 1 to Day 78

  9. Adverse events_clinical visit

    Clinical visit and check up by physicians

    Time frame: Day 1 to Day 36 and Day 78

  10. Adverse events-Diary

    Patient self report adverse events via diary

    Time frame: Day 1 to Day 78

07

Study locations

1 site
  • Taipei Medical University Hospital
    Taipei, Taiwan, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jan 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 14, 2023
StartActual
Nov 27, 2023
Primary completionActual
Jan 28, 2025
CompletionActual
Apr 27, 2025
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05985694
Lead sponsor
Advagene Biopharma Co. Ltd.
Collaborators
Taipei Medical University Hospital
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Nov 27, 2023
Primary completion
Jan 28, 2025
Completion
Apr 27, 2025
Last update
Sep 10, 2025

Study contacts

Yushen Hsu, Ph.D.
study chair · Advagene Biopharma
Han-Pin Kuo, MD. Ph.D.
study director · Taipei Medical University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heat-labile enterotoxin, E coli

Start the discussion